Amneal Pharmaceuticals, Inc.

NASDAQ:AMRX

Drug Manufacturers - Specialty & Generic

Healthcare
$21.88 -0.90%

-$0.15 today

Market cap
$7.62B
Beta
1.32
P/E (TTM)
43.4
EPS (TTM)
$0.37
52W Low $7.67High $16.61

Volume 1.91M

Average 1.75M

AMRX Net Receivables

Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.

Amneal Pharmaceuticals, Inc.NASDAQ: AMRX

Net Receivables · Q2 FY2026 · quarter ended Jun 2026

Net receivables rises 20.2% from a year ago

Net receivables stood at $1.02B at the end of Q2 FY2026, up 20.2% from a year earlier and up 13.1% from the prior quarter. Over 3 fiscal years it compounded at +8.2% a year.

Context

  • Net receivables amounted to 27.0% of total assets at the end of Q2 FY2026, up 2.2 pp from a year earlier.
  • Net receivables increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether net receivables keeps rising in the next quarterly balance sheet after a +20.2% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$1.02B+13.1% QoQ
Last fiscal yearDec 2025
$939.87M+21.2% YoY
Year agoJun 2025
$849.27M+20.2% since
Net Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+20.2%——
1 year+21.2%——
3-year CAGR+8.2%——
5-year CAGR——
10-year CAGR——

Net Receivables history

USD · from the balance sheet

Latest · FY2025
939.87M USD
Year-over-year change
+21.2%
4-year CAGR
+7.8%

Net Receivables vs competitors

How AMRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so net receivables is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +20.2% is the 2nd highest of 11, against a peer median of +2.2%.
  • Net receivables amounts to 27.0% of total assets for AMRX, versus a peer median of 10.2%.
AMRX Competitors
Net Receivables for AMRX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
RDYDr. Reddy's Laboratories LimitedSep 2026₹101.84B INR-15.7%+6.0%17.7%
VTRSViatris Inc.Jun 2026$3.67B USD+2.0%-6.9%10.5%
TEVATeva Pharmaceutical Industries LimitedJun 2026$3.49B USD-2.0%+0.1%8.8%
BHCBausch Health Companies Inc.Jun 2026$2.26B USD+2.4%+9.4%9.1%
AMRXAmneal Pharmaceuticals, Inc.Jun 2026$1.02B USD+20.2%+8.2%27.0%
PRGOPerrigo Company plcJun 2026$761.2M USD+7.7%-4.2%10.0%
INDVIndivior Pharmaceuticals IncJun 2026$287M USD+19.6%+5.0%23.3%
ANIPANI Pharmaceuticals, Inc.Mar 2026$255.43M USD+15.9%+19.3%18.0%
AMPHAmphastar Pharmaceuticals, Inc.Mar 2026$147.85M USD+1.7%+17.4%9.0%
EBSEmergent BioSolutions Inc.Mar 2026$121.6M USD-40.3%-19.1%9.2%
CPIXCumberland Pharmaceuticals Inc.Mar 2026$14.26M USD+36.0%+8.8%20.1%
Peer median (excluding AMRX) —+2.2%+5.5%10.2%

Competitors are the stored peer set for AMRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents247.79M25.98M91.54M110.55M310.87M
Short-term Investments01.82M2.2M1.87M0
Net Receivables694.74M741.79M645.66M775.73M939.87M
Inventory489.39M530.74M581.38M612.45M606.3M
Other Current Assets41.95M64.37M7.57M40.7M4.44M
Total Current Assets1.52B1.41B1.38B1.59B1.91B
Property, Plant & Equipment (Net)639M589.36M550.14M523.69M550.33M
Goodwill593.02M598.85M598.63M597.44M595.47M
Intangible Assets1.17B1.1B890.42M732.38M563.5M
Long-term Investments085.59M37.09M35.92M7.82M
Tax Assets00000
Other Non-current Assets20.61M17.63M18.43M24.21M49.98M
Total Non-current Assets2.42B2.39B2.09B1.91B1.77B
Total Assets3.94B3.8B3.47B3.5B3.68B
Account Payables131.08M166.84M143.57M259.84M254.67M
Short-term Debt30.61M89.96M213.13M324.21M21.58M
Tax Payables2.52M0000
Deferred Revenue00398.41M00
Other Current Liabilities120.1M263.11M3.91M222.36M525.5M
Total Current Liabilities677.24M752.8M846.6M1.13B881.63M
Long-term Debt2.72B2.63B2.43B2.16B2.61B
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities65.43M97.12M41.77M163.33M75.79M
Total Non-current Liabilities2.9B2.84B2.56B2.42B2.79B
Total Liabilities3.57B3.59B3.41B3.55B3.67B
Common Stock3.01M3.04M3.07M3.1M3.15M
Retained Earnings(276.2M)(406.18M)(490.18M)(607.06M)(535.01M)
Accumulated OCI(24.83M)9.94M(32.35M)(65.51M)(110.73M)
Other Stockholders Equity00000
Minority Interest6.63M(89.49M)41.52M64.73M76.76M
Total Equity366.97M208.93M61.3M(44.54M)5.96M
Total Debt2.88B2.85B2.75B2.59B2.74B
Net Debt2.63B2.82B2.66B2.48B2.43B

Amneal Pharmaceuticals, Inc.

NASDAQ:AMRX

Intrinsic Alpha fair value

Locked

Current Price

$21.88

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.